Characteristics of cost studies in HCT
| Study . | Publication year . | No. of study patients . | Types of transplants . | Costs/charges (median) . | Costs/charges adjusted to 2012 USD . | Time horizon . |
|---|---|---|---|---|---|---|
| Societal | ||||||
| Frey et al26 | 2002 | Inpatient (n = 26), Outpatient (n = 21) | Autologous | Inpatient: $40 985 USD | Inpatient: $51 639 USD | Beginning of HDT to discharge from the facility |
| Outpatient: $29 210 USD | Outpatient: $36 803 USD | |||||
| Hospital/healthcare system | ||||||
| Smith et al33 | 1997 | 58 | Autologous | PB: $45 792 USD | PB: $68 106 USD | Initial transplant hospitalization |
| BMT: $59 314 USD | BM: $88 217 USD | |||||
| Kline et al19 | 1998 | 46 | Both autologous and allogeneic | Mean charges: $243 550 USD | Mean charges: $338 676 USD | Initial transplant hospitalization |
| Lee et al21 | 2000 | 236 | Both autologous and allogeneic | Auto: $55 500 USD | Auto: $78 379 USD | Initial transplant hospitalization |
| Allo: $105 300 USD | Allo: $148 709 USD | |||||
| Van Agthoven et al62 | 2002 | 97 | Allogeneic | MRD BM: $98 334 USD | MRD BM: $179 987 USD | 2 y |
| MUD BM: $151 754 USD | MUD BM: $277 765 USD | |||||
| MRD PB: $98 977 USD | MRD PB: $181 163 USD | |||||
| Lee et al20 | 2002 | TCD (n = 47), IST (n = 98) | Allogeneic | TCD: $113 000 USD | TCD: $148 740 USD | 1 y |
| IST: $155 000 USD | IST: $204 024 USD | |||||
| Cordonnier et al32 | 2005 | MA (n = 12), NMA (n = 11) | Allogeneic | MA: €64 600 | MA: $109 710 USD | 1 y |
| NMA: €60 000 | NMA: $101 898 USD | |||||
| de Lissovoy et al17 | 2005 | TCD (n = 194); NTCD (n = 202) | Allogeneic | TCD: $145 115 USD | TCD: $185 728 USD | 6 mo |
| NTCD: $141 981 USD; | NTCD: $181 717 USD | |||||
| Svahn et al31 | 2006 | 93 | Allogeneic | €139 414 | $214 703 USD | 5 y |
| Saito et al24 | 2007 | MA (n = 185), RIC (n = 90) | Allogeneic | MA:$128 253 USD | MA: $153 893 USD | 1 y |
| RIC:$80 499 USD; | RIC: $96 592 USD; | |||||
| Saito et al23 | 2008 | 315 | Allogeneic | $128 800 USD | $154 549 USD | 1 y |
| Majhail et al35 | 2009 | UCB (n = 173) | Allogeneic | UCB: $137 654 USD | UCB: $145 435 USD | 100 d |
| MRD (n = 121), | MRD: $83 583 USD | MRD: $88 308 USD | ||||
| Majhail et al28 | 2010 | MRD (n = 27), MUD (n = 28), UCB (n = 91) | Allogeneic | Mean cost per day survived MRD: $3446 USD; MUD: $4050 USD; UCB: $4522 USD | Mean cost per day survived MRD: $3582 USD | 100 d |
| MUD: $4214 USD | ||||||
| UCB: $4700 USD | ||||||
| Third-party payer | ||||||
| Rizzo et al25 | 1999 | Inpatient (n = 115), Outpatient (n = 17) | Both autologous and allogeneic | Charges inpatient: $157 698 USD | Charges inpatient: $214 553 USD | 100 d |
| Outpatient: $110 879 USD | Outpatient: $150 854 USD | |||||
| Study . | Publication year . | No. of study patients . | Types of transplants . | Costs/charges (median) . | Costs/charges adjusted to 2012 USD . | Time horizon . |
|---|---|---|---|---|---|---|
| Societal | ||||||
| Frey et al26 | 2002 | Inpatient (n = 26), Outpatient (n = 21) | Autologous | Inpatient: $40 985 USD | Inpatient: $51 639 USD | Beginning of HDT to discharge from the facility |
| Outpatient: $29 210 USD | Outpatient: $36 803 USD | |||||
| Hospital/healthcare system | ||||||
| Smith et al33 | 1997 | 58 | Autologous | PB: $45 792 USD | PB: $68 106 USD | Initial transplant hospitalization |
| BMT: $59 314 USD | BM: $88 217 USD | |||||
| Kline et al19 | 1998 | 46 | Both autologous and allogeneic | Mean charges: $243 550 USD | Mean charges: $338 676 USD | Initial transplant hospitalization |
| Lee et al21 | 2000 | 236 | Both autologous and allogeneic | Auto: $55 500 USD | Auto: $78 379 USD | Initial transplant hospitalization |
| Allo: $105 300 USD | Allo: $148 709 USD | |||||
| Van Agthoven et al62 | 2002 | 97 | Allogeneic | MRD BM: $98 334 USD | MRD BM: $179 987 USD | 2 y |
| MUD BM: $151 754 USD | MUD BM: $277 765 USD | |||||
| MRD PB: $98 977 USD | MRD PB: $181 163 USD | |||||
| Lee et al20 | 2002 | TCD (n = 47), IST (n = 98) | Allogeneic | TCD: $113 000 USD | TCD: $148 740 USD | 1 y |
| IST: $155 000 USD | IST: $204 024 USD | |||||
| Cordonnier et al32 | 2005 | MA (n = 12), NMA (n = 11) | Allogeneic | MA: €64 600 | MA: $109 710 USD | 1 y |
| NMA: €60 000 | NMA: $101 898 USD | |||||
| de Lissovoy et al17 | 2005 | TCD (n = 194); NTCD (n = 202) | Allogeneic | TCD: $145 115 USD | TCD: $185 728 USD | 6 mo |
| NTCD: $141 981 USD; | NTCD: $181 717 USD | |||||
| Svahn et al31 | 2006 | 93 | Allogeneic | €139 414 | $214 703 USD | 5 y |
| Saito et al24 | 2007 | MA (n = 185), RIC (n = 90) | Allogeneic | MA:$128 253 USD | MA: $153 893 USD | 1 y |
| RIC:$80 499 USD; | RIC: $96 592 USD; | |||||
| Saito et al23 | 2008 | 315 | Allogeneic | $128 800 USD | $154 549 USD | 1 y |
| Majhail et al35 | 2009 | UCB (n = 173) | Allogeneic | UCB: $137 654 USD | UCB: $145 435 USD | 100 d |
| MRD (n = 121), | MRD: $83 583 USD | MRD: $88 308 USD | ||||
| Majhail et al28 | 2010 | MRD (n = 27), MUD (n = 28), UCB (n = 91) | Allogeneic | Mean cost per day survived MRD: $3446 USD; MUD: $4050 USD; UCB: $4522 USD | Mean cost per day survived MRD: $3582 USD | 100 d |
| MUD: $4214 USD | ||||||
| UCB: $4700 USD | ||||||
| Third-party payer | ||||||
| Rizzo et al25 | 1999 | Inpatient (n = 115), Outpatient (n = 17) | Both autologous and allogeneic | Charges inpatient: $157 698 USD | Charges inpatient: $214 553 USD | 100 d |
| Outpatient: $110 879 USD | Outpatient: $150 854 USD | |||||
PB indicates peripheral blood; HDT, high-dose therapy; TCD, T-cell depletion; IST, immunosuppressive therapy; NTCD, non–T cell-depleted; MA, myeloablative; NMA, nonmyeloablative; RIC, reduced intensity conditioning; MRD, matched related donor; UCB, umbilical cord blood; MUD, matched unrelated donor; USD, United States dollar; and €, Euro.